Author: Babajani, Gholamreza
Small-molecule- enzyme enhancement therapy has emerged as an attractive approach for the treatment of lysosomal storage diseases (LSDs), a broad group of genetic diseases caused by mutations in genes encoding lysosomal enzymes or proteins required for lysosomal function. Missense mutant lysosomal enzymes normally subjected to rapid disposal by ER-associated degradation (ERAD) can be stabilized by small molecule chaperones that increase residual enzyme activity largely by increasing the transport and maturation of the mutant enzyme. Mucopolysaccharidosis I (MPS I) and Gaucher disease were my research targets – two LSDs caused by a deficiency of alpha-L-iduronidase (IDUA) and β-glucocerebrosidase (GCase), respectively. My goals were two-fold: (1) To determine the proteostasis of a severely defective mutant lysosomal enzyme in plant cells. (2) To develop a plant-cell-based screening system to identify putative LSD therapeutics. For the former goal, post-ER trafficking of the severely malfolded L444P GCase protein, and some aspects of cellular homeostasis, were restored to different degrees by ERAD inhibitors and proteostasis regulators, which increased the steady-state levels of the mutant protein inside the plant cells and rescued a proportion of protein from proteolysis. For goal 2, I developed a plant-cell-screening tool for identifying putative small molecule therapeutics based on selecting for library molecules capable of enhancing the post-ER transport of missense mutant lysosomal enzymes. Since the recombinant variants were equipped with a signal peptide, and the expression cells - transgenic tobacco BY2 cells - possess no lysosomes, the assay was based on increased lysosomal enzyme activity in the secretion media. I first established the proof-of-principle for the assay (i.e. its selectivity and specificity) based on recombinant N370S GCase, and two characterized chaperones - ambroxol and N-(n-nonyl) deoxynojirimycin. Two IDUA mutant proteins that underlie MPS I disease (P533R- and R383H- IDUA), formed the basis of the plant-cell-based assay that was used to screen a library of 1,040 Food and Drug Administration-approved drugs. Downstream validation of the hits identified in the primary screening by secretion and heat denaturation assays resulted in the identification of a potential candidate molecule (‘X-372’) for P533R IDUA. Further development of this molecule may yield a therapeutic for MPS I disease.
Copyright is held by the author.
The author granted permission for the file to be printed and for the text to be copied and pasted.
Supervisor or Senior Supervisor
Thesis advisor: Kermode, Allison
Member of collection